| Carney, Carol |
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | NA | Saroglitazar Magnesium 1 mg | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 04/27 | 07/27 | | |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
| Recruiting | N/A | 10000 | Europe, US | | Target PharmaSolutions, Inc. | Hepatocellular Cancer | 10/24 | 10/24 | | |
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease |
|
|
| Recruiting | N/A | 15000 | US | | Target PharmaSolutions, Inc. | Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis | 07/25 | 07/25 | | |
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | N/A | 15000 | Europe, US | | Target PharmaSolutions, Inc. | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 07/36 | 07/36 | | |
| Wede, Kory |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
